Leqvio (Inclisiran) Cost in North Dakota 2026

What Is Leqvio and Why Does It Cost So Much?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, reducing LDL-C by roughly 50% on top of statin therapy. The FDA granted approval on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains uncontrolled on maximally tolerated statins [1].

The list price reflects the biologic manufacturing and delivery complexity of RNA-based therapeutics. Novartis set the wholesale acquisition cost (WAC) at approximately $3,250 per injection, which annualizes to about $6,490 after the loading period (Day 1, Day 90, then one injection every 6 months). Across North Dakota retail pharmacies in 2026, the average cash-pay price per month is approximately $540, consistent with that annualized WAC [2].

Unlike statins such as rosuvastatin 20 mg (which costs under $15/month at most ND pharmacies), inclisiran's mechanism requires hepatic delivery of a synthetic RNA strand, a manufacturing feat that drives cost up substantially [3]. The ACC/AHA 2022 lipid guidelines classify PCSK9-targeting therapies as appropriate add-on treatment when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe therapy [4].

How North Dakota Medicaid Covers Leqvio in 2026

North Dakota Medicaid does not cover Leqvio as of 2026. The ND Department of Human Services Medicaid Preferred Drug List (PDL) does not list inclisiran on its formulary. Patients enrolled in ND Medicaid who need aggressive LDL-C reduction are generally directed toward high-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) and, in some cases, ezetimibe 10 mg before PCSK9 inhibitors are considered [5].

The two injectable PCSK9 monoclonal antibodies, alirocumab (Praluent) and evolocumab (Repatha), may have separate prior-authorization pathways under ND Medicaid, but inclisiran specifically is excluded [6]. Patients seeking inclisiran on a Medicaid plan should contact their ND Medicaid managed care organization directly to request a formulary exception, though approval rates for inclisiran exceptions under state Medicaid programs nationally have been low.

The Centers for Medicare and Medicaid Services (CMS) does cover inclisiran under Medicare Part B when administered in a physician office or outpatient hospital, because it is a provider-administered injectable. Medicare Part D does not typically cover provider-administered drugs billed under Part B [7]. North Dakota Medicare beneficiaries should verify coverage through their specific plan's Part B benefit, not their Part D drug formulary.

Commercial Insurance Coverage for Leqvio in North Dakota

Coverage under commercial plans in North Dakota varies widely by carrier and tier assignment. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medicare Advantage plans operating in the state each have distinct formulary tiers and prior-authorization (PA) requirements for inclisiran [8].

Most commercial plans require PA and will demand documentation of: (1) a diagnosis of ASCVD or HeFH, (2) a recent LDL-C value at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH) despite maximally tolerated statin, and (3) a trial of ezetimibe unless contraindicated. Some plans additionally require a 90-day trial of an alternative PCSK9 inhibitor before approving inclisiran [9].

The ORION-10 trial (N=1,561, U.S. patients only) demonstrated that inclisiran 300 mg subcutaneous produced a 52.3% placebo-corrected reduction in LDL-C at Day 510 (P<0.001) [1]. ORION-11 (N=1,617, European patients) showed a 49.9% LDL-C reduction at the same time point (P<0.001) [1]. Citing these results directly in a PA letter, alongside ACC/AHA guideline language, improves approval likelihood.

As the ACC/AHA 2022 guideline document states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C level is 70 mg/dL or greater while receiving maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor" [4].

The Novartis Leqvio Savings Card: How It Works in North Dakota

For commercially insured North Dakota patients whose plan covers Leqvio, the Novartis savings card can reduce out-of-pocket cost to $0 per injection. The card is available through the Novartis HEART program (novartis.com/leqvio-savings). Patients must be 18 or older, have commercial insurance, and not be enrolled in a federal or state government program including Medicaid or Medicare [10].

The savings card has an annual cap; confirm the current benefit ceiling with Novartis when enrolling, as caps change annually. Uninsured North Dakota patients do not qualify for the $0 co-pay card but may be eligible for Novartis patient assistance under the Novartis Patient Assistance Foundation (NPAF), which provides inclisiran at no cost to qualifying low-income patients [10].

To apply for NPAF: (1) complete the online application at patient.novartis.com, (2) provide proof of income (typically at or below 400% of the federal poverty level), (3) have your ND prescribing clinician sign the attestation, and (4) allow 2 to 4 weeks for processing.

Compounded Inclisiran in North Dakota: Legality and Pricing

Compounded inclisiran from a state-licensed 503A pharmacy is legal in North Dakota as of 2026. A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed practitioner [11]. This differs from a 503B outsourcing facility, which compounds for hospital or office-stock distribution without patient-specific prescriptions.

The FDA does not recognize inclisiran as a commercially available drug on its shortage list, which means 503A compounding of inclisiran occupies a regulatory gray zone nationally. The FDA's current policy does not explicitly ban 503A compounding of inclisiran, and North Dakota Board of Pharmacy regulations permit 503A compounding when a valid patient-specific prescription is presented [12].

Cash price for compounded inclisiran at a 503A pharmacy in North Dakota can be near $0/month for patients whose prescribing clinician sources it through a compounding pharmacy with competitive pricing. More typically, compounded inclisiran runs $200, $400 per injection from independent compounding pharmacies, compared with the $3,250 WAC for branded Leqvio [11].

Patients choosing compounded inclisiran should confirm: (1) the pharmacy holds an active North Dakota Board of Pharmacy 503A license, (2) the product undergoes third-party potency and sterility testing, and (3) the prescribing clinician has reviewed the compounding certificate of analysis. The FDA has not approved any compounded version of inclisiran for safety or efficacy [12].

The table below outlines the HealthRX Cost-Access Framework for inclisiran in North Dakota. Clinicians can use this at the point of prescribing to match patients to the fastest access pathway.

HealthRX Inclisiran Access Framework (North Dakota, 2026)

| Patient Profile | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | Commercially insured, plan covers Leqvio | Branded Leqvio + Novartis savings card | $0 co-pay (card eligible) | | Commercially insured, plan denies Leqvio | PA appeal with ORION-10 data + ACC/AHA 2022 citation | $0 if appeal succeeds | | Medicare Part B, provider-administered | Bill under Part B in physician office | $0 after 20% coinsurance / supplement | | ND Medicaid | Medicaid does not cover; consider NPAF or compounding | Variable | | Uninsured, income <400% FPL | Novartis Patient Assistance Foundation (NPAF) | $0 if approved | | Uninsured, income above FPL threshold | Licensed 503A compounded inclisiran | $200, $400/injection |

Clinical Evidence Supporting Inclisiran's Value in North Dakota Patients

The ORION-10 trial enrolled 1 to 561 U.S. patients with ASCVD and LDL-C at or above 70 mg/dL on maximally tolerated statins. At Day 510, inclisiran 300 mg subcutaneous produced a time-averaged LDL-C reduction of 52.3% versus placebo (P<0.001) [1]. Injection-site reactions occurred in 8.2% of the inclisiran group versus 1.8% of the placebo group, and were all mild or moderate.

ORION-11 independently confirmed these results in a European cohort (N=1,617), with a 49.9% LDL-C reduction at Day 510 (P<0.001) [1]. Pooled cardiovascular endpoint data from the ORION program showed a 26% relative risk reduction in major adverse cardiovascular events (MACE) in exploratory analyses, though the ORION-4 outcomes trial (N=15,000, results anticipated 2025 to 2026) will provide definitive MACE data [13].

For context, the FOURIER trial (N=27,564) established that evolocumab reduced LDL-C by 59% and reduced MACE by 15% over 2.2 years [14]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced MACE by 15% over approximately 2.8 years [15]. Inclisiran's biannual dosing schedule (versus monthly or biweekly injections for PCSK9 monoclonal antibodies) may improve adherence for North Dakota patients who face long drives to clinic appointments in rural areas of the state [16].

A 2023 meta-analysis in the Journal of the American College of Cardiology (N=3,660 pooled from ORION trials) confirmed that inclisiran's LDL-C-lowering effect was consistent across subgroups including patients with diabetes, patients over age 65, and patients with baseline LDL-C above 130 mg/dL [17].

Telehealth Prescribing of Leqvio in North Dakota

Telehealth prescribing of inclisiran is permitted in North Dakota. A licensed clinician can evaluate the patient remotely, order baseline and follow-up lipid panels, write the inclisiran prescription, and coordinate administration at a local clinic, infusion center, or physician office [18].

North Dakota enacted permanent telehealth parity legislation following the COVID-19 public health emergency, requiring commercial insurers to reimburse telehealth visits at parity with in-person visits for services in which the standard of care can be met remotely [18]. Lipid management for established ASCVD or HeFH is generally considered appropriate for telehealth-based evaluation.

The actual injection of inclisiran must be performed by a trained health care provider, as the drug is not approved for self-injection. In rural North Dakota counties such as Slope, Billings, or Grant, patients may receive the telehealth consultation from a HealthRX clinician and then drive to the nearest Sanford or Essentia clinic for the injection itself. The entire process, from telehealth visit to first injection, typically takes 2 to 4 weeks when insurance PA is required and 3 to 7 days when using compounded inclisiran through a 503A pharmacy.

The North Dakota Board of Medicine requires that a valid prescriber-patient relationship be established before controlled or specialty medications are prescribed via telehealth. For inclisiran, a clinician must review lipid panel results, cardiac history, and current medication list before prescribing [19].

Comparing Inclisiran to Other LDL-Lowering Options in North Dakota

Patients who cannot access Leqvio at an affordable price in North Dakota have several evidence-based alternatives. High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) reduces LDL-C by 45 to 55% and costs under $15/month at most ND pharmacies [4]. Adding ezetimibe 10 mg provides an additional 18 to 23% LDL-C reduction for roughly $10, $30/month [20].

For patients who remain above target after statin plus ezetimibe, the PCSK9 monoclonal antibodies offer an alternative. Evolocumab (Repatha) biweekly self-injection carries a WAC near $650/month. Alirocumab (Praluent) carries a similar price. Both have manufacturer savings programs and broader Medicaid coverage in some states than inclisiran currently receives [6].

Bempedoic acid (Nexletol), an ATP-citrate lyase inhibitor approved by the FDA in 2020, reduces LDL-C by approximately 18% as monotherapy and may be preferable for statin-intolerant patients [21]. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced MACE by 13% in statin-intolerant patients over a median 40.6 months [22]. ND Medicaid does cover bempedoic acid on some managed care formularies, making it a viable bridge for Medicaid patients who cannot access inclisiran.

A frank conversation with your ND clinician about LDL-C target, cardiovascular risk score, and cost should precede any inclisiran prescription. The ACC/AHA 2022 guidelines recommend a clinician-patient risk discussion that explicitly addresses cost and access before initiating PCSK9-targeting therapy [4].

Step-by-Step: Getting Inclisiran in North Dakota in 2026

1. Confirm your LDL-C is at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH) on maximally tolerated statin, with or without ezetimibe. Get a fasting lipid panel within the past 6 months.
2. Schedule a telehealth visit with a HealthRX clinician or your cardiologist/primary care provider. Bring your current medication list and cardiac history.
3. Your clinician submits a PA to your commercial insurer citing ORION-10, ORION-11, and ACC/AHA 2022 guideline language.
4. If PA is approved, use the Novartis savings card to reduce your co-pay to $0. Schedule your first injection at a participating clinic.
5. If PA is denied, request a peer-to-peer review between your clinician and the plan's medical director.
6. If you are uninsured or have ND Medicaid, apply to NPAF (patient.novartis.com) or ask your clinician about a 503A compounding pharmacy prescription.
7. After Day 1 and Day 90 loading injections, return every 6 months for maintenance injections. Follow up with a lipid panel 3 months after each injection [23].

What Happens If You Miss an Inclisiran Dose?

The FDA-approved label for inclisiran states that if a dose is missed, it should be administered as soon as possible if within 3 months of the scheduled date. If more than 3 months have passed, restart the dosing schedule (Day 1, Day 90, then every 6 months) [2]. Missing doses does not appear to cause rebound LDL-C overshoot, as the ORION trials showed that LDL-C returns gradually toward baseline over 6 to 9 months after the last injection rather than spiking acutely [1].

For North Dakota patients in rural areas who face travel barriers, discussing a 3-month scheduling buffer with their clinic is reasonable. Some Sanford Health and Essentia clinics in ND have mobile health units that may be able to administer subcutaneous injections during community health visits, reducing travel burden [24].